February 27, 2017 / 11:08 PM / 9 months ago

BRIEF-Titan Pharma receives FDA communication on ropinirole implant INDA

Feb 27 (Reuters) - Titan Pharmaceuticals Inc:

* Titan Pharmaceuticals receives FDA communication on ropinirole implant investigational new drug application

* Titan Pharmaceuticals Inc - FDA has completed its initial review of ropinirole implant investigational new drug application

* Titan Pharmaceuticals-FDA requested that co hold initiation of clinical study pending submission of requested information and agency’s 30-day review

* Titan Pharmaceuticals-FDA indicated it will require final release test data on ropinirole implant, applicator used to insert implant before clearing ind

* Additionally, FDA is requesting that Titan identify a participating principal investigator for ropinirole study

* Titan Pharmaceuticals - expects to have final test data on implant, applicator within next several weeks Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below